Apollomics (NASDAQ:APLM) Stock Price Down 1.6% – What’s Next?

Shares of Apollomics Inc. (NASDAQ:APLM) traded down 1.6% during mid-day trading on Thursday . The company traded as low as $18.73 and last traded at $18.80. Approximately 1,802 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 16,077 shares. The stock had previously closed at $19.11.

Analyst Ratings Changes

Separately, Weiss Ratings cut Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Apollomics Stock Up 0.8%

The business has a 50 day moving average of $16.18 and a two-hundred day moving average of $17.60.

Hedge Funds Weigh In On Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC bought a new position in shares of Apollomics Inc. (NASDAQ:APLM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.